Yes, we are in clinical studies — phase II to be specific for WST-057. But our group already has some evidence in humans that other drugs in the same class appear to be working to reverse (in humans) the biological (nerve growth) and functional (sensory and quality of life) losses often seen with peripheral neuropathy. This gives us confidence we are on the right track.
One thing we chose with respect to WST-057 is that recycling this drug in a topical format — over 30 years of safety in a pill — gives us greater confidence in its safety. Phase I was all about safety — and our drug, not surprisingly, did not show any adverse effects. Now to prove that our drugs work well in many more patients. Wish us luck.